NATERA INC (NTRA)
US6323071042 - Common Stock
Taking everything into account, NTRA scores 4 out of 10 in our fundamental rating. NTRA was compared to 565 industry peers in the Biotechnology industry. The financial health of NTRA is average, but there are quite some concerns on its profitability. NTRA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year NTRA has reported negative net income.
In the past year NTRA had a positive cash flow from operations.
NTRA had negative earnings in each of the past 5 years.
NTRA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
NTRA has a better Return On Assets (-13.49%) than 85.20% of its industry peers.
The Return On Equity of NTRA (-24.44%) is better than 83.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.49% | ||
| ROE | -24.44% | ||
| ROIC | N/A |
ROA(3y)-35.86%
ROA(5y)-30.73%
ROE(3y)-68.88%
ROE(5y)-59.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NTRA has a better Gross Margin (57.66%) than 79.14% of its industry peers.
In the last couple of years the Gross Margin of NTRA has grown nicely.
NTRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.66% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.71%
GM growth 5Y5.07%
2. Health
2.1 Basic Checks
NTRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NTRA has been increased compared to 1 year ago.
NTRA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, NTRA has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 17.68 indicates that NTRA is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 17.68, NTRA belongs to the top of the industry, outperforming 91.80% of the companies in the same industry.
NTRA has a Debt/Equity ratio of 0.42. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.42, NTRA is doing worse than 72.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 17.68 |
ROIC/WACCN/A
WACC10.36%
2.3 Liquidity
A Current Ratio of 4.39 indicates that NTRA has no problem at all paying its short term obligations.
NTRA has a Current ratio of 4.39. This is comparable to the rest of the industry: NTRA outperforms 48.84% of its industry peers.
NTRA has a Quick Ratio of 4.23. This indicates that NTRA is financially healthy and has no problem in meeting its short term obligations.
NTRA has a Quick ratio of 4.23. This is comparable to the rest of the industry: NTRA outperforms 48.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.39 | ||
| Quick Ratio | 4.23 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 61.06% over the past year.
NTRA shows a strong growth in Revenue. In the last year, the Revenue has grown by 54.93%.
Measured over the past years, NTRA shows a very strong growth in Revenue. The Revenue has been growing by 33.25% on average per year.
EPS 1Y (TTM)61.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.63%
Revenue 1Y (TTM)54.93%
Revenue growth 3Y40.42%
Revenue growth 5Y33.25%
Sales Q2Q%63.9%
3.2 Future
Based on estimates for the next years, NTRA will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.77% on average per year.
The Revenue is expected to grow by 16.91% on average over the next years. This is quite good.
EPS Next Y46.85%
EPS Next 2Y29.43%
EPS Next 3Y25.78%
EPS Next 5Y18.77%
Revenue Next Year43.6%
Revenue Next 2Y27.56%
Revenue Next 3Y24.09%
Revenue Next 5Y16.91%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NTRA. In the last year negative earnings were reported.
Also next year NTRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NTRA's earnings are expected to grow with 25.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.43%
EPS Next 3Y25.78%
5. Dividend
5.1 Amount
No dividends for NTRA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NATERA INC
NASDAQ:NTRA (11/21/2024, 8:00:01 PM)
After market: 170 +0.64 (+0.38%)169.36
+1.48 (+0.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap22.36B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.49% | ||
| ROE | -24.44% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.66% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.96
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.39 | ||
| Quick Ratio | 4.23 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)61.06%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y46.85%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)54.93%
Revenue growth 3Y40.42%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y